HDACiDB: a database for histone deacetylase inhibitors

被引:14
作者
Murugan, Kasi [1 ]
Sangeetha, Shanmugasamy [2 ]
Ranjitha, Shanmugasamy [2 ]
Vimala, Antony [2 ]
Al-Sohaibani, Saleh [1 ]
Rameshkumar, Gopal [2 ]
机构
[1] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh 11451, Saudi Arabia
[2] Anna Univ, KBC Res Ctr, Bioinformat Lab, Madras 600044, Tamil Nadu, India
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2015年 / 9卷
关键词
cancer; drug likeness; histone deacetylase inhibitors; epigenetics; Lipinski's rule; molecular properties; DIFFERENTIATION; RESOURCE;
D O I
10.2147/DDDT.S78276
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
An histone deacetylase (HDAC) inhibitor database (HDACiDB) was constructed to enable rapid access to data relevant to the development of epigenetic modulators (HDAC inhibitors [HDACi]), helping bring precision cancer medicine a step closer. Thousands of HDACi targeting HDACs are in various stages of development and are being tested in clinical trials as monotherapy and in combination with other cancer agents. Despite the abundance of HDACi, information resources are limited. Tools for in silico experiments on specific HDACi prediction, for designing and analyzing the generated data, as well as custom-made specific tools and interactive databases, are needed. We have developed an HDACiDB that is a composite collection of HDACi and currently comprises 1,445 chemical compounds, including 419 natural and 1,026 synthetic ones having the potential to inhibit histone deacetylation. Most importantly, it will allow application of Lipinski's rule of five drug-likeness and other physicochemical property-based screening of the inhibitors. It also provides easy access to information on their source of origin, molecular properties, drug likeness, as well as bioavailability with relevant references cited. Being the first comprehensive database on HDACi that contains all known natural and synthetic HDACi, the HDACiDB may help to improve our knowledge concerning the mechanisms of actions of available HDACi and enable us to selectively target individual HDAC isoforms and establish a new paradigm for intelligent epigenetic cancer drug design. The database is freely available on the http://hdacidb.bioinfo.au-kbc.org.in/hdacidb/website.
引用
收藏
页码:2257 / 2264
页数:8
相关论文
共 50 条
  • [31] Histone deacetylase inhibitors in cancer therapy
    Lee, Min-Jung
    Kim, Yeong Sang
    Kummar, Shivaani
    Giaccone, Giuseppe
    Trepel, Jane B.
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 639 - 649
  • [32] Histone deacetylase inhibitors in clinical development
    Rosato, RR
    Grant, S
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (01) : 21 - 38
  • [33] Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
    Sanaei, Masumeh
    Kavoosi, Fraidoon
    ADVANCED BIOMEDICAL RESEARCH, 2019, 8 (01): : 63
  • [34] Histone Deacetylase Inhibitors in Cancer Therapy
    Sun, Yijie
    Sun, Yanyi
    Yue, Saichao
    Wang, Yaohe
    Lu, Fanghui
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (28) : 2420 - 2428
  • [35] New patented histone deacetylase inhibitors
    Wang, Haishan
    Dymock, Brian W.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (12) : 1727 - 1757
  • [36] Histone deacetylase inhibitors and genomic instability
    Eot-Houllier, Gregory
    Fulcrand, Geraldine
    Magnaghi-Jaulin, Laura
    Jaulin, Christian
    CANCER LETTERS, 2009, 274 (02) : 169 - 176
  • [37] Histone deacetylase inhibitors in cancer treatment
    Vigushin, DM
    Coombes, RC
    ANTI-CANCER DRUGS, 2002, 13 (01) : 1 - 13
  • [38] Histone deacetylase inhibitors in myelodysplastic syndrome
    Bhalla, K
    List, A
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2004, 17 (04) : 595 - 611
  • [39] Histone deacetylase inhibitors and cancer therapy
    La Thangue, NB
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 64 - 67
  • [40] Histone Deacetylase Inhibitors In Inflammatory Disease
    Halili, Maria A.
    Andrews, Melanie R.
    Sweet, Matthew J.
    Fairlie, David P.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (03) : 309 - 319